Hereditary Angioedema Treatment Market will reach a value of US$ 6,533.3 Mn by 2025 at a CAGR of 16.8%

# Hereditary Angioedema Treatment Market will reach a value of US$ 6,533.3 Mn by 2025 at a CAGR of 16.8% The incidence of genetic mutation is on the rise, which will benefit the [global market for treatments for hereditary angioedema](https://www.fortunebusinessinsights.com/industry-reports/hereditary-angioedema-treatment-market-100164). Hereditary angioedema treatment market size, share, and global trend by drug class (C-1 esterase inhibitors, Bradykinin Receptor Antagonist, Kallikrein Inhibitors), application (prophylaxis, treatment), route of administration (IV, subcutaneous), distribution channel (hospital pharmacy, retail pharmacy), and geography forecast until 2025 were recently published in a report by Fortune Business Insights. According to the report, the market for treating hereditary angioedema was worth **US$ 1883.1 million in 2017**. By the end of 2025, it is expected that the global market will have grown at a **CAGR of 16.8%** and will total **US$ 6533.3 Mn**. The report provides a detailed overview of the global market for hereditary angioedema treatments and divides it into various segments. The market for treating hereditary angioedema was valued at USD 1,883.1 million in 2017 and is anticipated to grow to USD 6,533.3 million by the end of 2025, at a CAGR of 16.8%. The high prevalence of hereditary angioedema in the area is responsible for the growth seen. For the duration of the forecast, North America might continue to dominate the global market (2018-2025). **Get Sample PDF Brochure:** https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/hereditary-angioedema-treatment-market-100164 The presence of an established healthcare system and increasing healthcare expenditure are a few factors anticipated to contribute to the expansion of the Hereditary Angioedema Treatment Market in North America. The report also predicts the market in Asia Pacific to witness impressive growth. Increasing medical tourism in nations such as China and India will create lucrative growth opportunities for the market in the region. Besides this, an increasing number of product innovations in the region backed by the high presence of hereditary angioedema drug manufacturers will give tailwinds to the growth witnessed by the Hereditary Angioedema Treatment Market. **Key Points Covered in the Hereditary Angioedema Treatment Market** * The Hereditary Angioedema Treatment market is driven by the increasing incidence of hereditary angioedema (HAE) and the growing awareness about the condition. * The market is segmented into various treatment options such as plasma-derived C1-esterase inhibitors, recombinant C1-esterase inhibitors, and bradykinin receptor antagonists. * The plasma-derived C1-esterase inhibitors segment is expected to hold the largest share of the market due to the high effectiveness and long-term safety of these products. * The market is also expected to grow due to the increasing use of self-administered treatments and the development of new therapies. * Key players in the market include CSL Behring, Shire, BioCryst Pharmaceuticals, Pharming Group, ViroPharma and Others **C-1 Esterase Inhibitor Segment to Dominate Global Market During Forecast Period** In terms of drug class, the C-1 esterase inhibitor is the most popular drug and dominated the global Hereditary Angioedema Treatment Market in 2017. The segment accounted for 61.3% of the global market in 2017. The trend is unlikely to change during the forecast period 2018-2025 owing to the drug’s reliability among patients and practitioners. Increasing awareness about the disorder and the rising prevalence of hereditary angioedema are some factors expected to drive the global Hereditary Angioedema Treatment Market during the forecast period. Additionally, technological developments in hereditary angioedema treatment devices and equipment are expected to boost the global market. According to the U.S. Hereditary Angioedema Association, hereditary angioedema may not necessarily occur due to prior familial history of the disease. In 25% of the cases, hereditary angioedema may arise due to spontaneous mutation of the gene called C-1 inhibitor. This is anticipated to enable growth in the global Hereditary Angioedema Treatment Market. On the flip side, the side effects and high cost associated with hereditary angioedema drugs and treatment is the major factor that may restrain the global Hereditary Angioedema Treatment Market. **Shire, CSL Behring, and Pharming Group NV to Lead the Global Market** The global Hereditary Angioedema Treatment Market is witnessing the entry of new players in the market. However, at present Pharming Group NV, Shire, and CSL Behring are together leading the global market owing to the organization’s strong distribution network. The report provides an elaborative analysis of the market dynamics and competitive landscape. Various key insights provided in the report are key strategies of leading market players, epidemiology of hereditary angioedema – for key countries, pipeline analysis, and introduction of new products/approvals (by major players). **Get More Insights On:** https://www.fortunebusinessinsights.com/industry-reports/hereditary-angioedema-treatment-market-100164 **Key Companies Covered in The Report** * CSL Behring * Shire plc. * Pharming Group NV * BIOCRYST PHARMACEUTICALS, INC. * Ionis Pharmaceuticals, Inc. * Attune Pharmaceuticals * Arrowhead Pharmaceuticals, Inc. * Adverum * Other prominent players